A. Trapman

HER2-low breast cancer shows a lower immune response compared to HER2-negative cases

M. Smid, A. Jager, C. V. van Deurzen, 2022, Scientific Reports.

How ADAM-9 and ADAM-11 Differentially From Estrogen Receptor Predict Response to Tamoxifen Treatment in Patients with Recurrent Breast Cancer: a Retrospective Study

Mieke Timmermans, J. Foekens, J. Klijn, 2005, Clinical Cancer Research.

Growth and metastatic behavior of molecularly well-characterized human breast cancer cell lines in mice

J. Foekens, M. Look, M. Timmermans, 2014, Breast Cancer Research and Treatment.

Prognostic value of receptors for insulin-like growth factor 1, somatostatin, and epidermal growth factor in human breast cancer.

J. Foekens, J. Klijn, H. Portengen, 1989, Cancer research.

Which cyclin E prevails as prognostic marker for breast cancer? Results from a retrospective study involving 635 lymph node-negative breast cancer patients.

Mieke Timmermans, Maxime P Look, J. Foekens, 2006, Clinical cancer research : an official journal of the American Association for Cancer Research.

Aberrant APOBEC3B Expression in Breast Cancer Is Linked to Proliferation and Cell Cycle Phase

M. Timmermans, P. Span, H. E. Balcioglu, 2023, Cells.

Which Cyclin E Prevails as Prognostic Marker for Breast Cancer? Results from a Retrospective Study Involving 635 Lymph Node–Negative Breast Cancer Patients

J. Foekens, J. Klijn, A. Sieuwerts, 2006, Clinical Cancer Research.